Experts told who “Lidochka” can help with obesity

At the round table in Komsomolskaya Pravda, endocrinologists, therapists and psychologists discussed the therapy of obesity with tyrzepatide. This substance acts on two receptors - GIP and GLP-1, while semaglutide affects only GLP-1. The reason for the discussion is the registration of the Russian generic "Tirliday" by the Ministry of Health in April 2026 (type 2 diabetes and obesity); the material is published by RTVI.

Professor Alexander Ametov called obesity a violation of metabolic health. According to the WHO, more than 185 countries are not expected to reduce the incidence by 2030; among patients with type 2 diabetes, obesity occurs in 85-90%. Tyrzepatide reduces appetite, reduces cravings for sweets, slows the emptying of the stomach and prolongs the feeling of satiety. Albumin binding provides a dosing regimen once a week.

In the SURMOUNT-1 study, patients at a dose of 15 mg lost an average of almost 23% of body weight and maintained the result. Among 1,032 people with prediabetes, 53 percent (almost 99 percent) did not develop diabetes over three years; the risk of developing it relative to placebo decreased by 94 percent. According to TABFAT, for 24 weeks, tyrzepatide increased the activity and volume of brown adipose tissue, and some white fat acquired the properties of “beige”. This extends the function of the drug beyond weight loss.

Treatment requires the supervision of an endocrinologist. Contraindication - medullary thyroid cancer. With diabetes, kidney disease and taking hypoglycemic drugs, dehydration and hypoglycemia are possible. After withdrawal, weight and metabolic risks may return without lifestyle adjustment and psychological support. A stable effect is possible when combining the drug with protein nutrition, a gradual increase in activity and work with a psychologist.

Tirliday is produced by Pharmasynthesis-Nord; six dosages (2.5-15 mg) are available. Nikita Puniya, Vice President of Pharmasynthesis Group for Commerce, reported on the ANVISA inspection and on the quality compliance with the original drug. He compared the price to the Mounjaro in Austria (from 330 euros, about 11 times more expensive). According to the company, in the five to six weeks after the launch, sales exceeded 100,000 cases. Patients on the forums call the drug "Lida" and "Lidochka".